{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:59:34Z","timestamp":1778558374965,"version":"3.51.4"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.diabet.2013.05.002","type":"journal-article","created":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T07:00:36Z","timestamp":1374044436000},"page":"290-298","source":"Crossref","is-referenced-by-count":35,"title":["The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes"],"prefix":"10.1016","volume":"39","author":[{"given":"P.","family":"Iyngkaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Anavekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Majoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a06","key":"10.1016\/j.diabet.2013.05.002_bib0005","first-page":"S38","article-title":"The management of the diabetic patient with prior cardiovascular events","volume":"4","author":"Fonarow","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.111.064097","article-title":"Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation","volume":"125","author":"Rafiq","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2013.05.002_bib0015","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/eurheartj\/ehi184","article-title":"Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure","volume":"26","author":"Petersson","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2013.05.002_bib0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cardiores.2003.11.024","article-title":"Interactions between the sympathetic nervous system and the kidneys in arterial hypertension","volume":"61","author":"Grisk","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2013.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/hc1102.105261","article-title":"Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease","volume":"105","author":"Zoccali","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2013.05.002_bib0030","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/CIRCULATIONAHA.110.948489","article-title":"Serious cardiovascular outcomes in diabetes: the role of hypoglycemia","volume":"123","author":"Yakubovich","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2013.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.05.002_bib0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tins.2013.01.004","article-title":"Hypertension in obesity: is leptin the culprit?","volume":"36","author":"Simonds","year":"2013","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.diabet.2013.05.002_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/157339910790909396","article-title":"Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance","volume":"6","author":"Masuo","year":"2010","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabet.2013.05.002_bib0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc09-1294","article-title":"Cardiac autonomic neuropathy in diabetes: a clinical perspective","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.05.002_bib0065","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.hrthm.2010.06.003","article-title":"Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis","volume":"7","author":"Volders","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.diabet.2013.05.002_bib0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.HYP.0000022063.50739.60","article-title":"Norepinephrine and concentric hypertrophy in patients with end-stage renal disease","volume":"40","author":"Zoccali","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2013.05.002_bib0075","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.2337\/diabetes.50.5.1180","article-title":"Impairment of coronary microvascular dilation in response to cold pressor\u2013induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging","volume":"50","author":"Nitenberg","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.05.002_bib0080","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/eurheartj\/ehs041","article-title":"The human sympathetic nervous system: its relevance in hypertension and heart failure","volume":"33","author":"Parati","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2013.05.002_bib0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/archinte.1985.00360060069008","article-title":"Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis","volume":"145","author":"Elias","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0090","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1681\/ASN.2006030204","article-title":"Cross-talk between the kidney and the cardiovascular system","volume":"17","author":"Amann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1464-5491.1999.00127.x","article-title":"Increased sympathetic activity during sleep and nocturnal hypertension in type 2 diabetic patients with diabetic nephropathy","volume":"16","author":"Nielsen","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.110.164780","article-title":"Early sympathetic activation in the initial clinical stages of chronic renal failure","volume":"57","author":"Grassi","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2013.05.002_bib0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/hr.2010.35","article-title":"The role of sympathetic nervous activity in renal injury and end-stage renal disease","volume":"33","author":"Masuo","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.diabet.2013.05.002_bib0110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1681\/ASN.V123602","article-title":"Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy","volume":"12","author":"Strojek","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jdiacomp.2007.05.003","article-title":"Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension","volume":"22","author":"Jawa","year":"2008","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2013.05.002_bib0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/HYPERTENSIONAHA.112.193870","article-title":"Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension","volume":"60","author":"Mahfoud","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2013.05.002_bib0125","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s001250051448","article-title":"Baroreflex sensitivity is depressed in microalbuminuric type I diabetic patients at rest and during sympathetic manoeuvres","volume":"42","author":"Lefrandt","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.05.002_bib0130","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0135","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.25.4.878","article-title":"Renal afferent denervation prevents hypertension in rats with chronic renal failure","volume":"25","author":"Campese","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2013.05.002_bib0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/HJH.0b013e3280119286","article-title":"Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation","volume":"25","author":"Hausberg","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2013.05.002_bib0145","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0150","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1681\/ASN.V12112427","article-title":"Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension","volume":"12","author":"Klein","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1523-1755.2002.00140.x","article-title":"Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rat","volume":"61","author":"Priyadarshi","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2013.05.002_bib0160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ki.2011.455","article-title":"Renal BOLD-MRI does not reflect renal function in chronic kidney disease","volume":"81","author":"Michaely","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2013.05.002_bib0165","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1997.103","article-title":"Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure","volume":"51","author":"Ye","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2013.05.002_bib0170","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1046\/j.1523-1755.2002.00636.x","article-title":"Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study","volume":"62","author":"Foley","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2013.05.002_bib0175","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2013.05.002_bib0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ajh\/1.1.91","article-title":"Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions","volume":"1","author":"Man in\u2019t Veld","year":"1988","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.diabet.2013.05.002_bib0185","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2013.05.002_bib0190","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/bmj.298.6681.1152","article-title":"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients","volume":"298","author":"Pollare","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2013.05.002_bib0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11906-008-0061-7","article-title":"Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy","volume":"10","author":"Sica","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.diabet.2013.05.002_bib0200","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.semnephrol.2007.07.003","article-title":"Should beta-blockers be used to control hypertension in people with chronic kidney disease?","volume":"27","author":"Hart","year":"2007","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0205","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3949\/ccjm.76a.09030","article-title":"Beta-blockers for hypertension: are they going out of style","volume":"76","author":"Che","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0210","first-page":"212","article-title":"Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol","volume":"12","author":"Marchi","year":"1995","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2013.05.002_bib0215","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","article-title":"Beta blockers in the management of chronic kidney disease","volume":"70","author":"Bakris","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2013.05.002_bib0220","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0225","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2013.05.002_bib0230","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","article-title":"Nebivolol: the somewhat-different beta-adrenergic receptor blocker","volume":"54","author":"Munzel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/000331978703800707","article-title":"Acute and short-term effects of clonidine in heart failure","volume":"38","author":"Giles","year":"1987","journal-title":"Angiology"},{"key":"10.1016\/j.diabet.2013.05.002_bib0240","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1681\/ASN.V1181469","article-title":"Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats","volume":"11","author":"Amann","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0245","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1023\/A:1007702132210","article-title":"Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension","volume":"12","author":"Krespi","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.diabet.2013.05.002_bib0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-2004-820915","article-title":"Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes","volume":"112","author":"Jacob","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.diabet.2013.05.002_bib0255","first-page":"S29","article-title":"Moxonidine improves insulin sensitivity in insulin-resistant hypertensives","volume":"17","author":"Haenni","year":"1999","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.diabet.2013.05.002_bib0260","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2013.05.002_bib0265","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1097\/HJH.0b013e32833c2100","article-title":"Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease","volume":"28","author":"Hausberg","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2013.05.002_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(94)90041-8","article-title":"Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients","volume":"74","author":"Aparicio","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0275","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0280","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","author":"ALLHAT Collaborative Research Group","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2013.05.002_bib0285","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/HJH.0b013e32833b912c","article-title":"Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?","volume":"28","author":"Chapman","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2013.05.002_bib0290","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM199904293401704","article-title":"Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure","volume":"340","author":"Ligtenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2013.05.002_bib0295","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1096\/fasebj.21.6.A1268-d","article-title":"The influence of statin therapy on resting sympathetic nerve activity in patients with heart failure","volume":"21","author":"Fisher","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.diabet.2013.05.002_bib0300","first-page":"CD004022","article-title":"Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride","author":"Graudal","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.diabet.2013.05.002_bib0305","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2337\/dc10-1722","article-title":"The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes","volume":"34","author":"Thomas","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.05.002_bib0310","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.111.062430","article-title":"Dietary sodium intake in heart failure","volume":"126","author":"Gupta","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2013.05.002_bib0315","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cardfail.2010.11.008","article-title":"Three gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure","volume":"17","author":"Lennie","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2013.05.002_bib0320","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3945\/ajcn.110.000174","article-title":"A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study","volume":"93","author":"Arcand","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabet.2013.05.002_bib0325","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ejheart.2007.03.003","article-title":"Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol","volume":"9","author":"Fraga","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2013.05.002_bib0330","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1681\/ASN.2007010009","article-title":"Exercise in the end-stage renal disease population","volume":"18","author":"Johansen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0335","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(12)60825-3","article-title":"New drugs, procedures, and devices for hypertension","volume":"380","author":"Laurent","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2013.05.002_bib0340","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2013.05.002_bib0345","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.111.00194","article-title":"Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension","volume":"61","author":"Hering","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2013.05.002_bib0350","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/HYPERTENSIONAHA.112.201186","article-title":"Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series","volume":"60","author":"Brinkmann","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2013.05.002_bib0355","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1681\/ASN.2011111062","article-title":"Renal denervation in moderate to severe CKD","volume":"23","author":"Hering","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0360","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2013.05.002_bib0365","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphys.2012.00010","article-title":"Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension","volume":"3","author":"Schlaich","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0370","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.numecd.2012.09.004","article-title":"Renal denervation in cardiometabolic disease: concepts, achievements and perspectives","volume":"23","author":"Grassi","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.diabet.2013.05.002_bib0395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2012.09.019","article-title":"First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study","volume":"162","author":"Davies","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0380","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/157339906777950589","article-title":"Baroreflex function: determinants in healthy subjects and disturbances in diabetes, obesity and metabolic syndrome","volume":"2","author":"Skrapari","year":"2006","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabet.2013.05.002_bib0385","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.002_bib0390","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cardfail.2010.09.004","article-title":"Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction","volume":"17","author":"Georgakopoulos","year":"2011","journal-title":"J Card Fail"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236361300092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236361300092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T12:29:51Z","timestamp":1646137791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236361300092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S126236361300092X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2013.05.002","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}